Mcdaniel Terry & Co. Sells 399 Shares of Luminex Corporation (LMNX)

Mcdaniel Terry & Co. trimmed its position in Luminex Corporation (NASDAQ:LMNX) by 1.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,776 shares of the medical instruments supplier’s stock after selling 399 shares during the period. Mcdaniel Terry & Co. owned 0.09% of Luminex Corporation worth $819,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the stock. Martingale Asset Management L P grew its stake in Luminex Corporation by 14.4% in the second quarter. Martingale Asset Management L P now owns 142,014 shares of the medical instruments supplier’s stock worth $3,000,000 after purchasing an additional 17,901 shares during the period. JPMorgan Chase & Co. grew its stake in Luminex Corporation by 35.5% in the second quarter. JPMorgan Chase & Co. now owns 52,058 shares of the medical instruments supplier’s stock worth $1,100,000 after purchasing an additional 13,632 shares during the period. Principal Financial Group Inc. grew its stake in Luminex Corporation by 12.1% in the second quarter. Principal Financial Group Inc. now owns 330,490 shares of the medical instruments supplier’s stock worth $6,980,000 after purchasing an additional 35,698 shares during the period. Prudential Financial Inc. grew its stake in Luminex Corporation by 4.6% in the second quarter. Prudential Financial Inc. now owns 67,180 shares of the medical instruments supplier’s stock worth $1,419,000 after purchasing an additional 2,960 shares during the period. Finally, Marshall Wace North America L.P. grew its stake in Luminex Corporation by 6.8% in the second quarter. Marshall Wace North America L.P. now owns 88,236 shares of the medical instruments supplier’s stock worth $1,853,000 after purchasing an additional 5,584 shares during the period. 78.37% of the stock is currently owned by institutional investors.

In related news, Director Robert J. Cresci sold 19,631 shares of the company’s stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $18.98, for a total value of $372,596.38. Following the completion of the transaction, the director now owns 260,358 shares of the company’s stock, valued at approximately $4,941,594.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Luminex Corporation (NASDAQ:LMNX) traded up 1.25% on Monday, reaching $19.38. The company’s stock had a trading volume of 61,668 shares. Luminex Corporation has a 1-year low of $17.64 and a 1-year high of $23.62. The company has a market capitalization of $854.10 million, a price-to-earnings ratio of 60.00 and a beta of 0.27. The firm’s 50 day moving average price is $19.56 and its 200-day moving average price is $19.65.

Luminex Corporation (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.09 by $0.11. The business had revenue of $76.50 million during the quarter, compared to analysts’ expectations of $75.45 million. Luminex Corporation had a return on equity of 4.81% and a net margin of 4.72%. The company’s revenue for the quarter was up 19.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.33 EPS. Equities analysts forecast that Luminex Corporation will post $0.51 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/09/11/mcdaniel-terry-co-sells-399-shares-of-luminex-corporation-lmnx.html.

Several equities research analysts recently weighed in on the company. ValuEngine raised Luminex Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Zacks Investment Research raised Luminex Corporation from a “hold” rating to a “strong-buy” rating and set a $22.00 target price on the stock in a research note on Thursday, August 24th. BidaskClub cut Luminex Corporation from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 9th. TheStreet cut Luminex Corporation from a “b” rating to a “c+” rating in a research note on Monday, August 7th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $21.00 target price on shares of Luminex Corporation in a research note on Friday, June 9th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $21.40.

About Luminex Corporation

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Institutional Ownership by Quarter for Luminex Corporation (NASDAQ:LMNX)

Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply